Partial restoration of protein synthesis rates by the small molecule ISRIB prevents neurodegeneration without pancreatic toxicity by Ortori, Catherine et al.
OPEN
Partial restoration of protein synthesis rates by the
small molecule ISRIB prevents neurodegeneration
without pancreatic toxicity
M Halliday1,8, H Radford1,8, Y Sekine2, J Moreno1, N Verity1, J le Quesne1,3, CA Ortori4, DA Barrett4, C Fromont5, PM Fischer5,
HP Harding2, D Ron2,6 and GR Mallucci*,1,7
Activation of the PERK branch of the unfolded protein response (UPR) in response to protein misfolding within the endoplasmic
reticulum (ER) results in the transient repression of protein synthesis, mediated by the phosphorylation of the alpha subunit of
eukaryotic initiation factor 2 (eIF2α). This is part of a wider integrated physiological response to maintain proteostasis in the
face of ER stress, the dysregulation of which is increasingly associated with a wide range of diseases, particularly
neurodegenerative disorders. In prion-diseased mice, persistently high levels of eIF2α cause sustained translational repression
leading to catastrophic reduction of critical proteins, resulting in synaptic failure and neuronal loss. We previously showed that
restoration of global protein synthesis using the PERK inhibitor GSK2606414 was profoundly neuroprotective, preventing
clinical disease in prion-infected mice. However, this occured at the cost of toxicity to secretory tissue, where UPR activation is
essential to healthy functioning. Here we show that pharmacological modulation of eIF2α-P-mediated translational inhibition
can be achieved to produce neuroprotection without pancreatic toxicity. We found that treatment with the small molecule ISRIB,
which restores translation downstream of eIF2α, conferred neuroprotection in prion-diseased mice without adverse effects on
the pancreas. Critically, ISRIB treatment resulted in only partial restoration of global translation rates, as compared with the
complete restoration of protein synthesis seen with GSK2606414. ISRIB likely provides sufficient rates of protein synthesis for
neuronal survival, while allowing some residual protective UPR function in secretory tissue. Thus, fine-tuning the extent of UPR
inhibition and subsequent translational de-repression uncouples neuroprotective effects from pancreatic toxicity. The data
support the pursuit of this approach to develop new treatments for a range of neurodegenerative disorders that are currently
incurable.
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The protein misfolding neurodegenerative disorders, which
include Alzheimer’s (AD) and Parkinson’s (PD) diseases,
amyotrophic lateral sclerosis (ALS), as well as the rare prion
disorders, have in common the presence of aggregates of
misfolded proteins in the brain associated with neuronal loss.
Individual diseases are characterised by the accumulation of
disease-specific proteins and stereotyped clinicopathological
phenotypes. While specific toxic effects for individual proteins,
including oligomeric and aggregated forms, have been
reported (see Winklhofer et al.1 for review), the mechanisms
of neuronal death remain unclear and as a result effective
therapies have been elusive. However, it is likely that common
mechanisms as well as disease-specific ones lead to
neurodegeneration in these disorders. Disruption of cellular
processes such as protein recycling and autophagy2 and
mitochondrial dysfunction3 contributes to the pathogenesis of
several diseases. Most recently, the concept of disruption of
proteostasis through endoplasmic reticulum (ER) stress and
the attendant unfolded protein response (UPR) has emerged
as a major contributor to neurodegenerative diseases.4,5
Under physiological conditions, UPR activation ensures
proteostasis is maintained through a combination of transla-
tional and transcriptional responses triggered by the accumu-
lation of misfolded proteins in the ER.6 One branch of the UPR
results in the transient repression of protein synthesis via the
phosphorylation of pancreatic ER kinase (PERK), which in
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turn phosphorylates the alpha subunit of eukaryotic initiation
factor 2 (eIF2). eIF2α-P prevents the formation of ternary
complex, blocking translation at the level of initiation. Depho-
sphorylation of eIF2α-P by its specific phosphatase GADD34
allows protein synthesis to resume.7
We previously showed that, in prion-diseased mice, rising
levels of misfolded prion protein (PrP) promote sustained
elevation of eIF2α-P in neurons, leading to the protracted,
uncompensated decline in global translation rates, resulting in
the loss of crucial proteins that contributes to synaptic failure
and neuronal death. Lowering eIF2α-P levels by genetic
manipulations restored translation and was profoundly neu-
roprotective, prolonging survival in prion-infected mice,8
leading to the prediction that the pharmacological inhibition
of PERK kinase activity to reduce eIF2α-P would be equally
effective in preventing disease. Correspondingly, the small
molecule GSK2606414,9 a highly specific PERK inhibitor,
completely restored vital protein synthesis rates, abrogating
neurodegeneration and preventing clinical disease in prion-
infected mice.8,10 Critically, these effects were downstream of
prion replication and PrP accumulation, and therefore not
specific to prion disease. Activated (phosphorylated) PERK-P
and eIF2α-P are found in brains of patients with AD, PD, prion
diseases and related disorders,11–15 and in several mouse
models of different neurodegenerative diseases.16–19 Hence,
the development of a small molecule targeting the UPR as a
generic treatment for the prevention neurodegeneration,
independently of disease-specific misfolded protein, is of
intense interest. Unfortunately, however, despite excellent
neuroprotection in the brain, treatment with GSK2606414 in
prion-diseased mice was associated with toxicity leading to
weight loss and mild hyperglycemia,10 a predicted conse-
quence of PERK inhibition in the pancreas.20 The pancreas
has an extensive secretory protein synthesis load, and
therefore requires some degree of eIF2α-P-mediated transla-
tional repression to survive ER stress. These findings beg the
question of whether restoration of protein synthesis to the level
required to prevent neurodegeneration is obligatorily linked to
dose-limiting toxicity, which is central to the further pursuit of
this approach to therapy.
eIF2α phosphorylation is a hub for signaling through other
eIF2α kinases, as part of the broader integrated stress
response (ISR). This leads to the inhibition of protein synthesis
and increased expression of the transcription factor ATF4 and
associated downstream signaling events, in response to
other cellular stresses mediated by various eIF2α kinases,
including PERK6 (Figure 1). Further, the regulation of protein
synthesis rates through eIF2α-P has a key role in learning
and memory.21 Recently, the small molecule N,N'-trans-
(cyclohexane-1,4-diyl)-bis-(2-(4-chlorophenoxy)acetamide (ISRIB),
which prevents ISR-mediated translational inhibition down-
stream of eIF2α-P (Figure 1), was shown to improve memory
in wild-type mice.22 Importantly, these beneficial effects of
ISRIB accrued without reported toxicity. We therefore asked if
the use of ISRIB, as an alternative approach to PERK
inhibition with GSK2606414, was neuroprotective in prion-
diseased mice and without adverse effects. We tested the
effect of treatment with ISRIB on clinical disease and
neuropathology in prion-infected animals, and examined the
pancreas for comparison with the effects of treatment with
GSK2606414. We measured protein synthesis rates to
compare the effects of the two compounds on UPR/ISR-
mediated translational attenuation to determine whether this
can be safely manipulated for the prevention of neurodegen-
eration without problematic toxicity.
Results
ISRIB penetrates the blood–brain barrier. We synthesized
ISRIB as described,22 and confirmed penetration of the
blood–brain barrier and measured mean brain:plasma ratios
at various doses in wild-type mice. Intra-peritoneal adminis-
tration of 0.25mg/kg of trans-ISRIB (henceforth termed
simply ISRIB), as used by Sidrauski et al.22 to enhance
memory in mice, gave a favorable pharmacokinetic profile
(Table 1), so this dose was used for treatment.
ISRIB reduces ATF4 levels and partially restores protein
synthesis rates in brains of prion-diseased mice. We
used tg37+/− mice23 infected with Rocky Mountain Labora-
tory (RML) prions, as used in previous studies.8,10,23–26
These mice show PERK/eIF2α-mediated translational repres-
sion at 9 weeks post inoculation (w.p.i.) and develop neuronal
loss progressing to clinical signs and death at ~ 12 w.p.i.8
Prion-infected mice were treated daily with 0.25mg/kg of
ISRIB or vehicle alone from 7 w.p.i., when synapse loss is
established as previously performed with GSK2606414.10
Uninfected animals were included as controls. Mice were
analyzed biochemically at 9 w.p.i., when prion-mediated UPR
Figure 1 Scheme of the PERK branch of the UPR. Unfolded proteins activate
PERK, which phosphorylates eIF2α. This represses translation at the level of
initiation. Some proteins, however, escape this repression and are preferentially
translated after eIF2α phosphorylation, such as ATF4, which leads to the translation
of the pro-apoptotic CHOP. Chronic translational repression leads to neurodegenera-
tion in prion disease. Signaling through the integrated stress response (ISR) can also
lead to eIF2α-P and translational repression. The sites of action of GSK2606414 and
ISRIB are shown
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activation occurs. High levels of eIF2α-P were seen by
western blotting of hippocampal protein samples from both
ISRIB and vehicle-treated animals, but ISRIB treatment
reduced levels of ATF4 markedly, consistent with its point of
action downstream of eIF2α-P, as previously described22
(Figure 2a). ISRIB treatment reversed UPR/ISR-mediated
translational repression and significantly increased global
protein synthesis rates in prion-diseased mice to ~ 70% of
levels seen in uninfected controls, compared with rates of
only 40% in vehicle-treated animals, as measured by
incorporation of [35S]-methionine into proteins in hippocampal
slices (Figure 2b).
ISRIB is neuroprotective in prion-diseased mice. Clinical
prion disease in mice is diagnosed by a combination of early
indicator and later confirmatory signs, the latter of which are
usually correlated with advanced neuronal loss.10 The clinical
course and incubation period are consistent for specific
strains of prions and mice. We found that none (0/12) of the
ISRIB-treated animals, but all (9/9) vehicle-treated mice
developed confirmatory signs of prion disease by 12 w.p.i.
on clinical observation (Table 2). Consistent with this,
neuropathological examination confirmed that ISRIB treat-
ment prevented neuronal loss in the hippocampus and
reduced typical prion spongiform pathology, in marked
contrast to extensive neurodegeneration and spongiform
degeneration due to untreated prion disease in vehicle-
treated mice (Figure 3a). Levels of total PrP and protease
resistant PrP (PrPSc) were similar in both groups of mice
(Figure 3b), as ISRIB acts downstream of prion replication.
Notably, ISRIB significantly increased survival in prion-
infected mice from 84±3 days post infection in vehicle-
treated mice (n= 9) to 96±4 days (n=12) (Figure 4) at which
point, however, despite being in good health, the animals had
to be killed because of loss of 20% of body weight, as per
protocol. At this stage, no signs of prion disease either
clinically or in terms of neurodegeneration were found.
ISRIB is not toxic to the pancreas, in contrast to the
PERK inhibitor GSK2606414. Our previous results using
the PERK kinase inhibitor, GSK2606414, similarly led to
weight loss after chronic treatment in prion-diseased mice.10
PERK− /−-knockout mice show early postnatal lethality and
exocrine pancreatic insufficiency,20 and it is predictable that
the pancreas is vulnerable to PERK inhibition. Owing to its
massive ER-protein synthesis load, pancreatic tissue needs
a degree of eIF2α-P-mediated translational repression to
survive ER stress, hence it might be expected that ISRIB
would be similarly toxic to the pancreas. Pancreatic exocrine
damage would be predicted to lead to weight loss and
inanition, and endocrine damage to glucose intolerance and
diabetes.
To understand the systemic effects of both compounds in
causing weight loss, we treated another group of prion-
infected mice for 5 weeks with either GSK2606414 or ISRIB
and examined the pancreas and measured blood glucose
levels. The latter were unaffected by ISRIB treatment but
were mildly but significantly elevated by GSK2606414
(Figure 5a), consistent with previous findings.10 However,
morphological examination of the pancreas showed that
chronic GSK2606414 treatment was toxic, causing ~50%
reduction in pancreatic weight (Figure 5b) and extensive
destruction of exocrine acinar pancreatic tissue (Figure 5c).
Critically, ISRIB treatment produced no detectable pancreatic
toxicity; pancreatic weights were normal (Figure 5b) and
structure and integrity of exocrine and endocrine pancreatic
tissues was preserved (Figure 5c). Thus, while reversal of
translational inhibition by both GSK2606414 and ISRIB is
neuroprotective, the two compounds have very different
adverse effect profiles on the pancreas.
ISRIB is a partial inhibitor of the integrated stress
response. To understand the basis of their diversity, we
compared the effects of GSK2606414 and ISRIB on cultured
pancreatic cells. To gage the intensity of the ISR, we
measured protein synthesis by puromycin incorporation into
newly synthesized proteins. As expected, exposure to the ER
stress-inducing agent thapsigargin led to marked attenuation
in new protein synthesis, which was nearly completely
reversed by GSK2606414 (Figure 6a). ISRIB, by contrast,
resulted in only partial restoration of protein synthesis in
thapsigargin-treated cells (Figure 6a), even at saturating
concentrations (Figure 6c), in contrast to GSK2606414
(Figure 6d). These effects matched the in vivo profiles of
the compounds, where ISRIB treatment led to ~ 70%
recovery of protein synthesis rates (Figure 2b), compared
with ~ 100% reported with GSK2606414 treatment.10
Restoration of protein synthesis by both agents was effaced
Table 1 Plasma concentration of trans-ISRIB in mice at 8 and 24 h following single intraperitoneal injection at a range of doses
Dose mg/kg Time (h) Plasma mean ng/ml±S.D. Brain mean ng/g±S.D. Mean ratio brain: plasma
Vehicle 8 NQ NQ NQ
Trans-ISRIB 0.25 8 345.3±44.7 186.9± 46.8 0.54
24 9.9±1.0 16.0± 1.6 1.62
2.5 8 721.6±60.1 254.6± 70.3 0.35
24 44.1±11.6 39.7± 12.6 0.9
5 8 369.7±114.4 160.3± 17.6 0.43
24 70.9±30.6 64.6± 9.2 0.91
Abbreviation: NQ, not quantifiable
Wild-type mice were given single doses of trans-ISRIB at 0.25, 2.5 and 5mg/kg by interperitoneal injection, and the plasma and brain concentrations of trans-ISRIB
were determined at 8 and 24 h after dosing in each case. The determined mean brain:plasma ratios indicated that trans-ISRIB (the active isomer) readily crossed the
blood–brain barrier, achieving good penetration into brain tissue at both 8 and 24 h. The lack of correlation between dose and the measured concentrations of trans-
ISRIB in the plasma and brain suggests a limitation to absorption of the compound, possibly due to the poor aqueous solubility of ISRIB. Trans-ISRIB at a concentration
of 0.25 mg/kg gave favorable brain penetration and was therefore used for all subsequent experiments. Concentrations shown are all mean±S.D. (n= 3)
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by washing cells free of the compound before thapsigargin
application, indicating that both compounds reversibly
engage their target in vivo (Figure 6a). To further compare
the two compounds, ISRIB and GSK2606414 were applied to
cells expressing a CHOP::luciferase construct that reflects
downstream activation of the ISR-induced CHOP gene27
(Figure 1). GSK2606414 treatment completely inhibited
tunicamycin-induced CHOP induction, while ISRIB only
partially reduced CHOP expression levels measured by
assessing relative luminescence induction by the two
compounds (Figure 6e), confirming the partial inhibitory
effect of ISRIB on UPR/ISR activation.
Discussion
The data show that treatment with ISRIB, as with the PERK
kinase inhibitor GSK2606414, is profoundly neuroprotective in
prion-diseased mice (Figures 3 and 4). Thus, we have shown
that inhibition of UPR/ISR-induced translation repression is
beneficial to neurons by treatment with a second small
molecule, acting at another point on this pathway. Importantly,
however, treatment with ISRIB did not cause pancreatic
toxicity, which is seen with GSK2606414, and has been
perceived as the major obstacle to therapeutic targeting of the
pathway to date (Figure 5). The differential toxicity on the
pancreas can be explained by the less extensive inhibition of
UPR/ISR activation by ISRIB compared with the effects of
PERK inhibition with GSK2606414 (Figure 6), independently
of their points of action in the pathway. Thus, ISRIB only
restores protein synthesis rates to ~ 70% of control levels
in vivo (Figure 2b) and ~ 50% in vitro (Figures 6a and b), even
at saturating concentrations of compound (Figure 6c). This is
in contrast to GSK2606414, which restores translation rates to
~ 100% in vivo10 and 90% in vitro (Figures 6a and b). ISRIB
essentially acts as a partial inhibitor of eIF2α-P-mediated
translational repression, although its precise mode and site of
action remain unknown.22
Together, these observations suggest that the attenuated
adverse effect profile of ISRIB compared with GSK2606414
relate to an intrinsic limitation on the extent of ISR inhibition
and resultant limited restoration of protein synthesis rates.
Thus, the beneficial effects of ISR-reversing drugs in prevent-
ing neurodegeneration do not require full suppression of the
response.
Figure 2 ISRIB restores translation in prion-diseased mice, downstream of
eIF2α phosphorylation. (a) ISRIB treatment (blue bars) lowers ATF4 levels while
leaving eIF2α-P unchanged in prion-diseased mice when compared with vehicle
treated (gray bars) animals, confirming its site of action downstream of eIF2α-P.
Representative immunoblots of hippocampal lysates and bar chart quantitating
relative levels of proteins in three independent samples are shown. (b) ISRIB
treatment partially restores translation as measured by [35S]-methionine
incorporation into hippocampal slices, compared with vehicle-treated animals
(n= 3-4 for each group). ***Po0.001, Student’s t-test, two-tailed. Bar graphs show
mean values± S.E.M.
Table 2 ISRIB treatment prevents clinical signs of prion disease in infected
mice
Vehicle-treated
mice
ISRIB-treated
mice
n=9 n=12
Early indicator signs
Rigid tail 9/9 7/12
Hind limb clasping 8/9 7/12
Unsustained hunched posture 4/9 0/12
Mild loss of coordination 9/9 7/12
Confirmatory signs
Impairment of righting reflex 5/9 0/12
Dragging of limbs (front/hind) 2/9 0/12
Sustained hunched posture 3/9 0/12
Scrapie incubation
Number of animals succumbing
to prion disease
9/9 0/12
Prion disease is diagnosed by the presence of two confirmatory clinical signs or
two early indicator and one confirmatory clinical signs. Nine out of nine vehicle-
treated mice exhibited a mixture of early indicator and confirmatory clinical
signs, indicating the development of clinical prion disease. Seven out of 12
ISRIB-treated mice exhibited early indicator clinical signs, but none progressed
to confirmatory signs and were not clinical diseased, demonstrating the
protective effects of ISRIB treatment on prion disease progression (vehicle
treated n= 9, ISRIB treated n=12)
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The problem of weight loss with ISRIB treatment is not
explained by pancreatic toxicity, nor by diabetes or other
obvious metabolic effect. This may reflect off-target effects of
ISRIB, or systemic consequences of persistent prion infection
unmasked by the survival of the treated mice. In any case the
survival of pancreatic tissue is marked advantage of partial
inhibition of the ISR.
The data have important implications for a number of
diseases in which the observation of UPR activation occurs,
raising the possibility of a generic treatment for multiple
disorders. Thus, raised PERK-P and eIF2α-P levels are seen
in patients with AD, PD and other protein misfolding
neurodegenerative disorders,11–15 and there are increasing
reports of beneficial UPR/ISR modulation in various neurode-
generation disease models.28–31 Unfortunately, ISRIB is not
itself a candidate for such therapies, given its high insolubility,
and new compounds are needed. Critically, however, the data
support the existence of a therapeutic window of UPR/ISR
inhibition that affords neuroprotection without pancreatic
toxicity, and mandate the pursuit of drugs that modulate this
pathway within this window for the treatment of protein-
misfolding neurodegenerative disorders.
Figure 3 ISRIB confers neuroprotection in prion-diseased mice, via a mechanism independent of prion replication. (a) Representative images of hematoxylin and eosin-
stained hippocampal sections from uninfected control (left hand panels) and prion-infected mice treated with vehicle (central panels) or ISRIB (right hand panels). Vehicle-treated
mice show extensive neuronal loss in the CA1-3 region, with associated spongiosis, while ISRIB treatment prevents neurodegeneration and reduces spongiosis. Scale bar, top
row 400 μm, bottom row 50 μm). (b) ISRIB treatment does not affect the levels of total PrP and PrPSc. Total PrP and PrPSc levels, detected with and without proteinase K (PK)
digestion, were equivalent in prion-infected mice treated with vehicle or ISRIB. Representative immunoblots of three independent hippocampal lysate samples for total PrP and
PrPSc after PK (50 μg/ml) digestion. Control samples are from mice inoculated with normal brain homogenate
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Materials and Methods
Prion infection of mice. All animal work conformed to UK regulations and
institutional guidelines, performed under Home Office guidelines. Tg37+/− 23 mice
were inoculated with 1% brain homogenate of Chandler/RML prions aged
3–4 weeks, as described.24 Animals were culled when they developed clinical signs
of prion disease or lost 20% of body weight from the start of the study. Control mice
received 1% normal brain homogenate.
Compounds. The trans isomer of ISRIB was prepared as described.22 LC-MS
(system: Shimadzu UFLCXR–Applied Biosystems API2000; column: Phenomenex
Gemini-NX 3 µm–110 Å-C18, 50 x 2 mm, at 40 °C; elution: 0.5 ml/min, 5 to 98% B in
A linear gradient over 2 min, then 98% B isocratic for 2 min, where A: 0.1% HCOOH
in H2O, B: 0.1% HCOOH in MeCN; UV detection at 220 nm), tR 2.96 min (trans-
ISRIB), purity495%; MS (ESI+): m/z 451.1 [M+H]+, C22H26Cl2N2O4 requires 451.1
MW. NMR in accordance with Sidrauski et al.22
Dosing of mice. ISRIB was administered at 0.25 mg/kg once daily by
intraperitoneal injection or vehicle alone (45% saline, 50% PEG 400, 5% DMSO)
from 7 w.p.i. Treatment with GSK2606414 was by oral gavage twice daily with
50 mg/kg GSK2606414 from 7 w.p.i. as described.10
Figure 4 ISRIB treatment significantly extends survival in prion-infected animals
compared with vehicle-treated mice. Kaplan–Meier plot, controls n= 9 (black bar), vehicle
n= 9 (gray bar), ISRIB treated n= 12 (blue bar). **Po0.005, Mantel–Cox test
Figure 5 ISRIB is not toxic to the pancreas, unlike GSK2606414. (a) GSK2606414 treatment (green bar) mildly raises blood glucose levels compared with control (black bar),
vehicle-treated (gray bar) and ISRIB-treated (blue bar) mice (n= 6–9 for each group). (b) GSK2606414 treatment leads to a significant reduction in pancreas weight, while ISRIB
treatment has no effect (n= 3–6 for each group). (c) Representative images of hematoxylin and eosin-stained pancreas sections. GSK2606414 treatment leads to extensive
destruction of exocrine acinar pancreatic tissue, while ISRIB-treated tissue is histologically normal. Scale bar= 200 μm. *Po0.05, ***Po0.001, Student’s t-test, two-tailed. Bar
graphs show mean values±S.E.M.
Figure 6 GSK2606414 fully inhibits UPR/ISR-induced translational repression, whereas ISRIB only partially inhibits translational attenuation. (a) Immunoblot of
puromycinylated (nascent) proteins, phosphorylated eIF2α and total eIF2α recovered from lysates of AR42j rat pancreatic acinar cells and resolved by SDS–PAGE. Where
indicated the cells were exposed to the ER stress-inducing agent thapsigargin (Tg, 0.3 μM) in the presence or absence of ISRIB (100 nM) or the PERK kinase inhibitor
GSK2606414 (1 μM) for 30 min before lysis. Puromycin (10 μg/ml) was added during the last 10 min of the incubation. Where indicated (‘Washout’) the cells were exposed to the
aforementioned concentration of ISRIB or GSK2606414 for 30 min, washed thoroughly with media and incubated further for 1.5 or 7.5 h, before thapsigargin challenge and
puromycin labeling. The extent of puromycin labeling (‘Translation’) integrated across the surface of each lane is stated below the immunoblot (this value is set arbitrarily to 100 in
the reference lane 1, and scaled linearly in the other lanes). (b) Reversal of ISR-mediated inhibition of protein synthesis in the experimental conditions described in a (Lane 1, 2, 3
and 6) was quantified by integrating the puromycinylated protein signal across the surface of each lane and applying the algebraic operator: Rn= [(Pn− PTg)÷(PUT−PTg)] × 100.
Rn is the reversal in lane n. Pn, PUT and PTg are the puromycinylated protein signals from the sample of interest (lane n), the untreated sample (lane 1) and the sample exposed to
thapsigargin alone (lane 2), respectively. Shown are mean values±S.E.M. (n= 4, *Po0.05, Student’s t-test). (c) Blot: immunoblot of puromycinylated (nascent) proteins,
phosphorylated eIF2α and total eIF2α recovered from lysates of AR42j rat pancreatic acinar cells and resolved by SDS–PAGE. Where indicated the cells were exposed to the ER
stress-inducing agent thapsigargin (TG, 0.3 μM) in the presence or absence of the indicated concentrations of ISRIB for 30 min before lysis. Puromycin (10 μg/ml) was added
during the last 10 min of the incubation. Bar chart: reversal of ISR-mediated inhibition of protein synthesis in the experiment described in ‘a’ was quantified by integrating the
puromycinylated protein signal across the surface of each lane and applying the algebraic operator: Rn= [(Pn−PTg)÷(PUT− PTg)] × 100. Rn is the reversal in lane n. Pn, PUT and
PTg are the puromycinylated protein signals from the sample of interest (lane n), the untreated sample (lane 2) and the sample exposed to thapsigargin alone (lane 10),
respectively. Shown are mean values± variation in an experiment reproduced twice. (d) Blot: as in ‘a’ above, but applying the indicated concentrations of GSK2606414. Bar chart:
as in (c) above, but pertaining to GSK2606414. (e) Luciferase expression in CHO cells expressing a luciferase reporter construct under control of the CHOP promoter.
Tunicamycin treatment leads to robust luciferase expression, which is completely inhibited by GSK2606414 treatment. ISRIB treatment only partially reduces expression (n= 9 for
each group). Shown are mean values± S.E.M, *Po0.05, ***Po0.001 Student’s t-test, two-tailed
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Immunoblotting. Protein samples were isolated from hippocampi using protein
lysis buffer (150 mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS
and 50 mM Tris pH8.0) supplemented with Phos-STOP and protease inhibitors
(Roche, Welwyn Garden City, UK). UPR proteins and PrP levels were determined
by resolving 20 μg of protein on SDS–PAGE gels, transferred onto nitrocellulose or
PVDF membranes and incubated with primary antibodies for total PrP and PrPSc
(ICSM35 1 : 10,000; D-GEN), eIF2α-P, eIF2α (1 : 1000; Cell Signaling, Leiden,
Netherlands), ATF4 (CREB-2, 1 : 1000; Santa Cruz, Santa Cruz, CA, USA).
Horseradish peroxidase-conjugated secondary antibodies (1 : 5000; Dako, Glostrup,
Denmark) were applied and protein visualized using enhanced chemiluminescence
(GE Healthcare, Little Chalfont, UK) and quantitated using ImageJ. Antibodies
against GAPDH (1 : 5000; Santa Cruz) were used to determine loading.
Protein synthesis rates. Protein synthesis rates were calculated by
measuring [35S]-methionine incorporation into proteins in acute hippocampal slices,
as described.8,10 In brief, hippocampal slices were prepared with a tissue chopper
(McIlwain) and dissected in an oxygenated cold (2° to 5 °C) sucrose artificial
cerebrospinal fluid (ACSF) containing 26 mM NaHCO3, 2.5 mM KCl, 4 mM MgCl2,
0.1 mM CaCl2 and 250 mM sucrose. Slices were allowed to recover in normal ACSF
buffer while being oxygenated at 37 °C for 1 h in 95% O2/5% CO2, and then
incubated with 5.7 mBq of [35S]-methionine label for 1 h. Samples were washed and
homogenized in 1 × passive lysis buffer (Promega, Fitchburg, WI, USA), and
proteins were precipitated with 25% trichloroacetic acid (TCA) (Sigma, Gillingham,
UK). TCA lysates were then placed on Whatman filters, washed with 70% industrial
methylated spirits and acetone, and then placed into scintillation cocktail buffer.
Incorporation of radiolabel was measured by scintillation counting (WinSpectral,
Wallac, Coventry, UK).
Histology. Paraffin-embedded brains and pancreases were sectioned at 5 μm
and stained with hematoxylin and eosin (H&E) as described.8,10
Detection of ISRIB by LC-MS/MS. Blood and brain tissue were collected 8
or 24 h after dosing from mice treated with one doses of 0.25, 2.5 or 5 mg/kg trans-
ISRIB, or vehicle. Blood plasma (up 0.2 ml, exact volume measured) was diluted with
water to 0.2 ml and extracted with 0.4 ml of chloroform/methanol 2 : 1. After vortex
mixing (10 min) and centrifugation (10 000 g, 10 min), the lower layer was dried with
vacuum centrifugation and reconstituted in 50 μl of methanol. Brain tissue (one
complete half, about 0.25 g weighed exactly) was homogenized in 0.5 ml of chloroform/
methanol 2 : 1 and further processed exactly as the plasma samples. ISRIB
quantitative analysis (using external standards) was performed by LC-MS/MS using a
4000 QTRAP mass spectrometer (Applied Biosystems, Foster City, CA, USA)
equipped with a turbo ion source and LC series 10 AD VP (Shimadzu). The mobile
phase was a water/acetonitrile gradient modified with 0.1% formic acid using a Agilent
Poroshell 120 SB-C18 2.1 × 50mm2 (2.7 μm), which was maintained at 40 °C. LC-MS/
MS multiple reaction monitoring used a precursor ion of mass/charge ratio (m/z) 452
and a product ion of m/z 265 in positive electrospray ionization mode for trans-ISRIB.
Data analysis was performed with Analyst 1.4.1 in the quantitative mode.
Cell culture. AR42j cells were cultured in DMEM supplemented with 10% Fetal
calf serum (FetalClone II, Thermo Scientific, Loughborough, UK), 2 mM l-glutamine,
1 × Penicillin/Streptomycin and 1 × non-essential amino-acid solution and were
maintained at 37 °C with 5% CO2. CHO-KI CHOP::luciferase cells were cultured in
DMEM/F12(Ham) (Gibco, Paisley, UK) supplemented with 10% Fetal calf serum,
2 mM L-glutamine and 1 × Penicillin/Streptomycin, and were maintained at 37 °C
with 5% CO2.
Puromycin labeling and immunoblot analysis. The effects of ER
stress on puromycinylated protein levels, total and phosphorylated eIF2α in cells
were determined as previously described.32 In brief, 1 × 106 AR42j cells were plated
in 60 mm dishes. Two days later, culture media was changed to fresh media, and
cells were treated with vehicle (dimethyl sulfoxide) or thapsigargin in the presence
or absence of the indicated concentration of inhibitors for 30 min. For puromycin
labeling, 10 μg/ml puromycin was added during the last 10 min before harvest. Cells
were lysed with lysis buffer (1% Triton X-100, 50 mM Tris-HCl (pH 7.4), 150 mM
NaCl, 1 mM EDTA, 10% Glycerol, 2 mM PMSF, 10 μg/ml aprotinin, 4 μg/ml
Pepstatin and 4 μM Leupeptin). After centrifugation at 21 130 × g for 10 min,
supernatants were mixed with SDS–PAGE sample buffer. To detect puromycinylated
protein or eIF2α, 40 or 13 μg of total protein, respectively, was subjected to 12%
SDS–PAGE and transferred onto PVDF membrane. Immunoblot detection was
conducted using primary antibodies for puromycinylated protein (described in
Schmidt et al.33), phospho-eIF2alpha-Ser51 (Epitomics, Burlingame, CA, USA) or
total eIF2α, and IR800 or IR680 conjugated secondary antisera followed by
scanning on a Licor Odyssey scanner (Licor, Cambridge, UK). Scanned images
were quantified using imageJ software.
CHOP::luciferase assay. CHO::KI cells stably transfected with a CHOP::
luciferase reporter27 were plated at a density of 1 × 105 per well in a six-well plate
and left to grow overnight. Cells were treated for 6 h with 5 μg/ml tunicamycin or
vehicle only (100% DMSO) and then extracted using the Steady-Glo luciferase
assay system (Promega) before being quantified using the Glomax 96 microplate
luminometer (Promega). ISRIB and GSK2606414 were incubated with 5 μg/ml
tunicamycin for 6 h at 1 or 20 μM, respectively, before assaying as above.
Statistical analyses. Statistical analyses were performed using Prism V6
software (Graphpad, La Jolla, CA, USA) using Student’s t-test for data sets with
normal distribution and a single intervention. ANOVA testing was performed using
one-way analysis with Tukey’s post-hoc test for multiple comparisons. For Kaplan–
Meier analysis, Mantel–Cox analysis was used.
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